Table 1.

Baseline characteristics and clinical outcomes of 14 re-hospitalized COVID-19 patients after recurrent positive test of SARS-CoV-2 RNA

Characteristics	Case 1		Case 2		Case 3		Case 4		Case 5		Case 6		Case 7		Case 8		Case 9		Case 10		Case 11		Case 12		Case 13		Case 14
	1st	2nd	1st	2nd	1st	2nd	1st	2nd	1st	2nd	1st	2nd	1st	2nd	1st	2nd	1st	2nd	1st	2nd	1st	2nd	1st	2nd	1st	2nd	1st	2nd
Age, years	50		30		61		53		31		56		40		57		30		20		39		70		56		29
Sex (M/F)	Female		Male		Male		Female		Male		Male		Male		Male		Female		Male		Male		Male		Male		Female
Disease condition	S	Mo	Mo	Mo	Mo	Mo	Mo	Mo	Mo	Mi	Mo	Mo	Mo	Mo	Mo	Mo	Mi	Mi	Mo	Mo	Mo	Mo	Mo	Mo	Mo	Mo	Mo	Mo
Respiratory rate	21	18	20	18	22	22	20	22	20	21	25	19	20	20	20	21	20	21	22	18	20	26	20	20	22	20	21	20
Time from onset of symptoms to admission	8	2	5	1	5	2	6	2	18	2	10	4	3	1	4	3	14	1	5	5	7	1	21	2	6	1	6	9
Time from onset of RNA (+) to admission	1	2	2	1	1	2	1	2	6	2	1	4	1	1	1	3	2	1	5	5	1	1	1	2	2	1	2	9
Time from onset of RNA (+) to RNA (−)	9	3	17	2	13	4	4	4	10	4	6	8	9	6	33	15	5	4	10	6	4	5	18	9	12	4	5	14
Time from onset of RNA (−) to RNA (+)	29		12		19		40		26		22		7		17		22		19		30		10		22		16
Time from discharge to RNA (+)	11		8		14		14		21		15		1		12		10		13		17		7		17		11
Total days in hospital	27	4	19	4	18	5	30	4	9	5	13	7	16	11	38	18	15	8	13	6	17	7	22	19	15	6	8	8
Common symptoms
Fever	√	×	×	×	√	×	√	×	√	×	√	×	√	×	√	×	√	×	√	×	√	×	×	×	√	×	×	×
Cough	√	×	√	×	×	×	√	×	√	×	√	×	√	×	√	×	×	×	√	×	√	×	×	×	×	×	√	√
Short of breath	×	×	×	×	×	×	×	×	×	×	×	×	×	×	√	×	×	×	×	×	×	×	×	×	×	×	×	×
Diarrhea	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	√	×	×	×	×	×	×	×	×	×	×	×
Lack of appetite	√	×	×	×	√	×	√	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	√	×	×	×	×	×
Weakness	√	×	√	×	×	×	√	×	×	×	√	×	√	×	×	×	×	×	×	×	×	×	√	×	√	×	×	×
Muscle pain	×	×	×	×	×	×	√	×	×	×	×	×	×	×	×	×	×	×	√	×	√	×	×	×	×	×	×	×
Exposure history
Clear exposure		√	√	√		√		√		√		√	√	√		√	√	√	√	√		√	√	√	√	√	√	√
Unclear exposure	√				√		√		√		√				√						√
Comorbidities
Respiratory disease	×		×		×		×		×		×		×		×		×		×		×		×		×		×
Gastrointestinal diseases	×		×		×		×		×		×		×		×		×		×		×		×		×		×
Cardiovascular system disease	×		×		×		√		×		×		×		×		×		×		×		×		×		×
Nervous system disease	√		×		×		×		×		×		×		×		×		×		×		×		×		×
Endocrine system disease	×		×		×		×		×		×		×		×		×		×		×		×		×		×
Malignant tumor	×		×		×		×		×		√		×		×		×		×		×		×		×		×
Blood system diseases	×		×		×		√		×		×		×		×		×		×		×		×		×		×
Treatments
Antibiotic treatment	√	×	×	×	√	×	√	×	×	×	√	×	×	×	×	×	×	×	×	×	×	×	×	×	√	×	×	√
Antifungal treatment	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Antiviral treatment	√	√	√	×	√	√	√	√	√	√	√	√	√	√	√	×	√	√	√	×	√	√	√	√	√	×	√	√
Glucocorticoids	√	×	×	×	√	×	√	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	√	×	×	×
Nebulized IFN-α	√	×	×	×	×	×	×	×	√	×	√	×	√	×	×	√	√	√	×	×	√	×	×	×	√	√	√	√
Immunoglobulin	×	×	×	×	×	×	×	×	×	×	√	×	×	×	×	×	×	×	×	×	×	×	×	×	√	×	×	×
Lianhua Qingwen	√	×	√	√	√	×	√	×	√	×	√	×	√	×	√	√	×	×	√	√	√	×	×	×	√	×	×	×

S severe, Mo moderate, Mi mild, IFN-α α-interferon